Efficacy and safety profile of dupilumab for the treatment of atopic dermatitis in children and adolescents: A systematic review and meta‐analysis

Abstract

AbstractBackgroundDupilumab is the first biologic approved for the treatment of moderate‐to‐severe atopic dermatitis (AD) in children and adolescents. Previous systematic reviews explored the effectiveness and safety of dupilumab in adults with AD. However, the underlying mechanisms of AD can vary among different age groups, emphasizing the need for separate investigation into the use of dupilumab in children and adolescents with AD.ObjectiveTo evaluate the efficacy and safety of dupilumab in children and adolescents with AD based on evidence from clinical trials and observational studies.MethodsThe process of meta‐analysis was conducted according to preferred reporting items for systematic reviews and meta‐analyses guidelines.ResultsSeven clinical trials and 11 observational studies involving 1275 children and adolescents with AD were eligible for quantitative analysis. Overall, the pooled percentages of eczema area and severity index (EASI) 50, EASI 75, EASI 90, EASI 100, and investigator's global assessment (IGA) 0/1 were 72.9% (95% CI: 61.6%–81.9%), 57.4% (48.1%–66.2%), 31.3% (24.0%–39.7%), 29.7% (23.3%–37.0%), and 35.2% (29.3%–41.5%). With prolonged treatment time, an increase was seen in the pooled rate of EASI response, indicating that dupilumab may provide sustained benefits for children and adolescents over the long term. The reported adverse events were primarily mild and manageable, with an overall incidence rate of 7.2% across clinical trials and 7.6% across observational studies.ConclusionDupilumab was an effective and safe treatment option for children and adolescents with AD, with positive results observed from long‐term use and an acceptable safety profile. More long‐term, high‐quality, controlled studies in different regions are needed for further verification.